Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RIBOMIC Completes Enrollment in Early Phase 2 Achondroplasia Study
Details : RBM-007 (umedaptanib pegol) is a novel oligonucleotide-based aptamer, with potent anti-FGF2 activity and is expected to treat Achondroplasia.
Brand Name : RBM-007
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 03, 2024
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RBM-007
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC’s research facilities in Tokyo, has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, known to ...
Brand Name : RBM-007
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : RBM-007
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RBM-007
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Midwest Eye Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration
Details : Further analysis of Phase 2 TOFU data and results from the RAMEN study in previously treated wAMD show no benefit of RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity, monotherapy or the combination over Eylea in any of the st...
Brand Name : RBM-007
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 23, 2022
Lead Product(s) : RBM-007
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Midwest Eye Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RBM-007
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia
Details : RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC’s research facilities in Tokyo.
Brand Name : RBM-007
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 15, 2020
Lead Product(s) : RBM-007
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RBM-007
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : AJU Pharma
Deal Size : $6.0 million
Deal Type : Licensing Agreement
RIBOMIC Enters License Agreement with AJU Pharma
Details : Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 17, 2020
Lead Product(s) : RBM-007
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : AJU Pharma
Deal Size : $6.0 million
Deal Type : Licensing Agreement
Lead Product(s) : RBM-007,Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)
Details : First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 19, 2020
Lead Product(s) : RBM-007,Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?